Literature DB >> 23165094

IT Future of Medicine: from molecular analysis to clinical diagnosis and improved treatment.

Valeria Zazzu1, Babette Regierer, Alexander Kühn, Ralf Sudbrak, Hans Lehrach.   

Abstract

The IT Future of Medicine (ITFoM, http://www.itfom.eu/) initiative will produce computational models of individuals to enable the prediction of their future health risks, progression of diseases and selection and efficacy of treatments while minimising side effects. To be able to move our health care system to treat patients as individuals rather than as members of larger, divergent groups, the ITFoM initiative, proposes to integrate molecular, physiological and anatomical data of every person in 'virtual patient' models. The establishment of such 'virtual patient' models is now possible due to the enormous progress in analytical techniques, particularly in the '-omics' technology areas and in imaging, as well as in sensor technologies, but also due to the immense developments in the ICT field. As one of six Future and Emerging Technologies (FET) Flagship Pilot Projects funded by the European Commission, ITFoM with more than 150 academic and industrial partners from 34 countries, will foster the development in functional genomics and computer technologies to generate 'virtual patient' models to make them available for clinical application. The increase in the capacity of next generation sequencing systems will enable the high-throughput analysis of a large number of individuals generating huge amounts of genome, epigenome and transcriptome data, but making it feasible to apply deep sequencing in the clinic to characterise not only the patient's genome, but also individual samples, for example, from tumours. The genome profile will be integrated with proteome and metabolome information generated via new powerful chromatography, mass spectrometry and nuclear magnetic resonance techniques. The individualised model will not only enable the analysis of the current situation, but will allow the prediction of the response of the patient to different therapy options or intolerance for certain drugs.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23165094     DOI: 10.1016/j.nbt.2012.11.002

Source DB:  PubMed          Journal:  N Biotechnol        ISSN: 1871-6784            Impact factor:   5.079


  7 in total

Review 1.  New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.

Authors:  Armel Hervé Nwabo Kamdje; Paul Faustin Seke Etet; Lorella Vecchio; Richard Simo Tagne; Jeremie Mbo Amvene; Jean-Marc Muller; Mauro Krampera; Kiven Erique Lukong
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

2.  Communicating genetics and smoking through social media: are we there yet?

Authors:  Sylviane de Viron; L Suzanne Suggs; Angela Brand; Herman Van Oyen
Journal:  J Med Internet Res       Date:  2013-09-09       Impact factor: 5.428

Review 3.  Virtual patients--what are we talking about? A framework to classify the meanings of the term in healthcare education.

Authors:  Andrzej A Kononowicz; Nabil Zary; Samuel Edelbring; Janet Corral; Inga Hege
Journal:  BMC Med Educ       Date:  2015-02-01       Impact factor: 2.463

Review 4.  Epigenetic mechanisms in schizophrenia.

Authors:  Schahram Akbarian
Journal:  Dialogues Clin Neurosci       Date:  2014-09       Impact factor: 5.986

5.  Computational modelling of energy balance in individuals with Metabolic Syndrome.

Authors:  Yvonne J W Rozendaal; Yanan Wang; Peter A J Hilbers; Natal A W van Riel
Journal:  BMC Syst Biol       Date:  2019-02-26

Review 6.  Translational genomics.

Authors:  Martin Kussmann; Jim Kaput
Journal:  Appl Transl Genom       Date:  2014-05-10

Review 7.  Ten Years of EWAS.

Authors:  Siyu Wei; Junxian Tao; Jing Xu; Xingyu Chen; Zhaoyang Wang; Nan Zhang; Lijiao Zuo; Zhe Jia; Haiyan Chen; Hongmei Sun; Yubo Yan; Mingming Zhang; Hongchao Lv; Fanwu Kong; Lian Duan; Ye Ma; Mingzhi Liao; Liangde Xu; Rennan Feng; Guiyou Liu; The Ewas Project; Yongshuai Jiang
Journal:  Adv Sci (Weinh)       Date:  2021-08-11       Impact factor: 16.806

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.